[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methyl 4-methylbenzenesulfonate | 502434-59-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methyl 4-methylbenzenesulfonate
• 英文别名: ((25)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)methyl 4-methylbenzenesulfonate；((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)methyl 4-methylbenzenesulfonate；(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ylmethyl-4-methylbenzensulfonate；(2S)-2-tosyloxymethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazine；[(2S)-4-methyl-2,3-dihydro-1,4-benzoxazin-2-yl]methyl 4-methylbenzenesulfonate
• CAS: 502434-59-5
• 化学式: C₁₇H₁₉NO₄S
• 分子量: 333.408
• InChiKey: NIFVBDAGWQSHBT-AWEZNQCLSA-N

物化性质

• 沸点：
  497.3±38.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methyl 4-methylbenzenesulfonate 在 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoic acid
  参考文献：
  名称：

  Discovery of selective indole-based prostaglandin D2 receptor antagonist

  摘要：

  A series of N-benzoyl-2-methylindole-3-acetic acids were synthesized and biologically evaluated as prostaglandin (PG) D-2 receptor antagonists. Some of the selected compounds significantly inhibited OVA-induced vascular permeability in guinea pig conjunctiva after oral dosing. Structure-activity relationship study is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.014
• 作为产物：
  描述：

  对甲苯磺酰氯 、 (S)-2-hydroxymethyl-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 [(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT

  摘要：

  公式（I）所代表的吲哚衍生物化合物及其盐由于公式（I）所代表的化合物结合到PGD2受体并显示拮抗活性，因此认为它们对预防和/或治疗过敏疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身组织细胞增生症、全身组织细胞活化障碍、过敏性休克、气道收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎、荨麻疹）、由于伴有瘙痒行为（如搔抓和敲打）而次生产生的疾病（如白内障、视网膜脱离、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、自身免疫疾病、慢性关节风湿病、胸膜炎、溃疡性结肠炎和肠易激综合征等疾病的预防和/或治疗可能是有用的。

  公开号：

  EP1600440A1

文献信息

• Design and synthesis of new prostaglandin D2 receptor antagonists
  作者：Maki Iwahashi、Eiji Takahashi、Motoyuki Tanaka、Yoko Matsunaga、Yutaka Okada、Ryoji Matsumoto、Fumio Nambu、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2011.08.007

  日期：2011.9

  To identify new cost-effective prostaglandin D2 (DP) receptor antagonists, a series of novel 3-benzoylaminophenylacetic acids were synthesized and biologically evaluated. Among those tested, some representative compounds were found to be orally available. Receptor selectivity and rat PK profiles were also evaluated. The structure–activity relationship (SAR) study is presented.

  为了确定新的具有成本效益的前列腺素D 2（DP）受体拮抗剂，合成了一系列新型的3-苯甲酰基氨基苯基乙酸，并对其进行了生物学评估。在测试的化合物中，发现有一些代表性的化合物可口服。还评估了受体选择性和大鼠PK谱。提出了结构-活性关系（SAR）研究。
• Indole derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Iwahashi Maki

  公开号：US20060089353A1

  公开（公告）日：2006-04-27

  An indole derivative compound represented by formula (I) (wherein the symbols in the formula are as mentioned in the specification) and a salt thereof Since the compounds represented by formula (I) binds to PGD 2 receptors and shows antagonistic activity, they are believed to be useful for prevention and/or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, systemic mast cell activating disorder, anaphylaxis shock, airway contraction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis, urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleep disorder) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, autoimmune disease, chronic articular rheumatism, pleuritis, ulcerative colitis and irritable bowel syndrome.

  一种印地安蓝衍生物化合物，其化学式表示为(I)（其中化学式中的符号如说明书中所述），以及其盐。由于化合物(I)与PGD2受体结合并表现出拮抗活性，因此它们被认为对预防和/或治疗过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞病、全身性肥大细胞激活症、过敏性休克、气道收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎、荨麻疹）、由于瘙痒行为（如搔抓和敲打）而次生产生的炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、自身免疫性疾病、慢性关节风湿病、胸膜炎、溃疡性结肠炎和肠易激综合征等疾病有用。
• Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
  申请人：Iwahashi Maki

  公开号：US20050222216A1

  公开（公告）日：2005-10-06

  A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and/or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

  一种由公式（I）表示的羧酸化合物：（公式中符号的含义如规范中所述）和包括该化合物的药物制剂。由于公式（I）表示的化合物结合到DP受体并显示DP受体的拮抗活性，因此它对预防和/或治疗过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞增生症，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管痉挛，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱离，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如抓挠和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等方面具有用处。
• Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
  申请人：Naganawa Atsushi

  公开号：US20070004716A1

  公开（公告）日：2007-01-04

  A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.

  化合物的化学式为（I），其中公式中的符号与说明书中的含义相同，其盐、溶剂化物或前药具有DP受体结合和DP受体拮抗活性。因此，它可用于预防和/或治疗过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞病、伴随全身性肥大细胞激活的疾病、过敏性休克、支气管收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎和荨麻疹）、由于瘙痒行为（如搔抓和敲打）引起的炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等疾病的治疗。由于它特异性地结合于DP受体，并且弱地结合于其他前列腺素受体，因此可以作为副作用较小的药物。
• Phenylacetic Acid Compound
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20140357630A1

  公开（公告）日：2014-12-04

  A compound represented by formula (I), wherein R 1 represents a hydrogen atom, etc., R 2 and R 3 each independently represents a hydrogen atom, optionally oxidized C1-4 alkyl group or optionally protected hydroxyl group, or R 2 and R 3 taken together represent optionally oxidized C2-5 alkylene group, R 4 represents an optionally oxidized C1-6 alkyl group, etc., R 5 represents an optionally oxidized C1-6 alkyl group, etc., R 6 represents an optionally oxidized C1-6 alkyl group, etc., m represents 0 or an integer from 1 to 3, n represents 0 or an integer from 1 to 4, and i represents 0 or an integer from 1 to 7.

  化合物的化学式为（I），其中R1代表氢原子等，R2和R3各自独立地代表氢原子，可选的氧化C1-4烷基或可选择保护的羟基，或者R2和R3一起代表可选的氧化C2-5亚烷基，R4代表可选的氧化C1-6烷基等，R5代表可选的氧化C1-6烷基等，R6代表可选的氧化C1-6烷基等，m代表0或1至3的整数，n代表0或1至4的整数，i代表0或1至7的整数。